Enveric Biosciences to Showcase Therapeutic Developments at 2025 BIO International Convention

Enveric Biosciences is participating in the 2025 BIO International Convention, showcasing its business strategy and therapeutic developments. The company is advancing its lead molecule, EB-003, for neuropsychiatric disorders. Enveric is leveraging its proprietary Psybrary platform to create a comprehensive intellectual property portfolio of novel drug candidates. With a market capitalization of $3.11 million, Enveric aims to advance EB-003 to clinical trials and explore licensing opportunities for other compounds.

Title: Enveric Biosciences to Showcase Advancements at 2025 BIO International Convention

Enveric Biosciences (NASDAQ: ENVB) is set to participate in the 2025 BIO International Convention, taking place from June 16-19 in Boston, Massachusetts. The biotechnology company, dedicated to developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, will be showcasing its business strategy and recent therapeutic developments during the event.

During the convention, Joseph Tucker, Ph.D., CEO and Director of Enveric, will conduct one-on-one meetings with registered investors and potential partners. The meetings will highlight the company’s business and development strategy, recent corporate achievements, and anticipated milestones [1][2][3].

Enveric Biosciences is leveraging its unique discovery and development platform, Psybrary™, to create a robust intellectual property portfolio of novel drug candidates. The company's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity without inducing hallucinations in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while exploring licensing opportunities for other compounds from its patented Psybrary™ platform [1][2][3].

The company is headquartered in Naples, FL, with offices in Cambridge, MA, and Calgary, AB, Canada. With a market capitalization of $3.11 million, Enveric aims to continue its efforts in developing innovative treatments for psychiatric and neurological disorders [1][2][3].

References

[1] https://www.biospace.com/press-releases/enveric-biosciences-announces-participation-in-2025-bio-international-convention
[2] https://financialpost.com/pmn/business-wire-news-releases-pmn/enveric-biosciences-announces-participation-in-2025-bio-international-convention
[3] https://www.ncnewsonline.com/news/national/enveric-biosciences-announces-participation-in-2025-bio-international-convention/article_99c25977-cad2-519e-be14-1ce53648361e.html